A Vaccine for Schistosomiasis, "SchistoShield"

血吸虫病疫苗“SchistoShield”

基本信息

  • 批准号:
    10011501
  • 负责人:
  • 金额:
    $ 70.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-01-01 至 2023-02-28
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Schistosomiasis is a major parasitic disease which could impact up to a billion people in 74 countries. Current control strategies rely primarily on anti-parasitic drugs alone (praziquantel) which has proven inadequate due to both reinfection and the inherent threat of drug resistance. We have developed a potent schistosomiasis vaccine, termed SchistoShield®, targeting a functionally important antigen (Sm-p80) formulated with a potent immune- stimulator (GLA-SE). SchistoShield® has been exhaustively tested in rodents, rabbits, and baboons and has exhibited protection at all parasitic life-cycle stages including larvae, worms, and egg laying, survival, and excretion. We are completing our Phase II SBIR grant research focused on manufacture, lyophilization, and fill/finish of the antigen and will be entering into three clinical trials (first an NIH funded Phase 1 human trial in the USA, and next two Phase 1b trials funded by the European union which will be performed in Burkina Faso and Madagascar in Africa) beginning in the first quarter of 2020. To support our upcoming trials, this Phase IIb grant will focus on studies required to ensure stability of the vaccine drug product (DP) for the duration of the trials as required by regulatory agencies. The research will include assessing long-term stability, formal shipping studies, and development of a sensitive potency assay suitable for later stage clinical development. The potency assay will include immunization into mice followed by antibody titers after a single injection. We will forcibly degrade our antigen using simulated real-life conditions and test the altered protein for retention of immunological function using our potency assay. The goal will be to identify which quality parameters are directly indicative of a loss of potency. At the end of these studies we will have our DP on stability, formal shipping methods identified, a sensitive potency assay developed, and have identified critical quality parameters of potency of the vaccine. All these studies are required in preparation for Phase 2 and 3 clinical trials and future licensure and deployment.
项目摘要 血吸虫病是一种主要的寄生虫病,可能影响74个国家的10亿人。电流 控制策略主要依靠单独的抗寄生虫药物(吡喹酮),由于 再感染和耐药性的内在威胁。我们已经研制出一种有效的血吸虫病疫苗, 称为SchistoShield®,靶向功能重要的抗原(Sm-p80), 刺激剂(GLA-SE)。SchistoShield®已在啮齿动物、兔子和狒狒中进行了详尽的测试, 在所有寄生虫生命周期阶段(包括幼虫、蠕虫和产卵、存活)均表现出保护作用, 排泄我们正在完成我们的第二阶段SBIR赠款研究,重点是生产,冻干, 抗原的填充/完成,并将进入三个临床试验(第一个是NIH资助的1期人体试验, 美国,接下来的两项由欧盟资助的1b期试验将在布基纳法索进行 和非洲马达加斯加),从2020年第一季度开始。 为了支持我们即将进行的试验,IIb期赠款将重点用于确保疫苗稳定性所需的研究 按照监管机构的要求,在试验期间提供制剂(DP)。研究将包括 评估长期稳定性、正式运输研究和开发适用于以下方面的灵敏效价测定 后期临床开发。效价测定将包括对小鼠进行免疫接种,然后进行抗体检测 单次注射后的滴度。我们将使用模拟现实生活条件强制降解抗原,并测试 使用我们的效价测定,改变蛋白质以保留免疫功能。我们的目标将是确定 质量参数直接指示效力的损失。 在这些研究结束时,我们将有我们的DP稳定性,正式的运输方法确定,一个敏感的 开发了效价测定,并确定了疫苗效价的关键质量参数。所有这些 研究需要为2期和3期临床试验以及未来的许可和部署做准备。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DARRICK Albert CARTER其他文献

DARRICK Albert CARTER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DARRICK Albert CARTER', 18)}}的其他基金

Adjuvanted Recombinant Candidates to Prime / Boost COVID-19 RNA Vaccines
带佐剂的重组候选物可用于启动/增强 COVID-19 RNA 疫苗
  • 批准号:
    10325834
  • 财政年份:
    2021
  • 资助金额:
    $ 70.66万
  • 项目类别:
Developing a Screen for New Adjuvants to Enhance RNA Vaccines
开发增强 RNA 疫苗的新佐剂筛选方案
  • 批准号:
    10189513
  • 财政年份:
    2020
  • 资助金额:
    $ 70.66万
  • 项目类别:
A Vaccine for Lymphatic Filariasis, LFGuard™
淋巴丝虫病疫苗 LFGuard™
  • 批准号:
    10200657
  • 财政年份:
    2019
  • 资助金额:
    $ 70.66万
  • 项目类别:
A Vaccine for Lymphatic Filariasis, LFGuard™
淋巴丝虫病疫苗 LFGuard™
  • 批准号:
    10082074
  • 财政年份:
    2019
  • 资助金额:
    $ 70.66万
  • 项目类别:
A Vaccine for Lymphatic Filariasis, LFGuard™
淋巴丝虫病疫苗 LFGuard™
  • 批准号:
    10408790
  • 财政年份:
    2019
  • 资助金额:
    $ 70.66万
  • 项目类别:
CruziScreen, a recombinant antigen-based screening test for Chagas disease
CruziScreen,一种基于重组抗原的恰加斯病筛查测试
  • 批准号:
    9407719
  • 财政年份:
    2017
  • 资助金额:
    $ 70.66万
  • 项目类别:
JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer
JOC-x:打开肿瘤紧密连接以治疗癌症的化疗结合物
  • 批准号:
    10020907
  • 财政年份:
    2016
  • 资助金额:
    $ 70.66万
  • 项目类别:
A recombinant protein that increases engraftment of hematopoietic stem cells
一种增加造血干细胞植入的重组蛋白
  • 批准号:
    9048950
  • 财政年份:
    2016
  • 资助金额:
    $ 70.66万
  • 项目类别:
Tumor Tight Junction Opener + Chemotherapy Conjugates to Treat Cancer
肿瘤紧密连接开放剂化疗结合物治疗癌症
  • 批准号:
    8647718
  • 财政年份:
    2014
  • 资助金额:
    $ 70.66万
  • 项目类别:
A Vaccine for Schistosomiasis, "SchistoShield"
血吸虫病疫苗“SchistoShield”
  • 批准号:
    10341126
  • 财政年份:
    2013
  • 资助金额:
    $ 70.66万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 70.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 70.66万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 70.66万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 70.66万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 70.66万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 70.66万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 70.66万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 70.66万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 70.66万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 70.66万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了